I believe Esperion were thinking the same and were (perhaps still are) looking for ways to improve manufacturing and reduce cost of their recombinant ApoA-I Milano/phospholipid complex. http://www.esperion.com/modules/xnews/article.php?storyid=4 I guess MDCO is in the same boat. No idea what expression system they use/d. Another player with a recombinant ApoA-I: